Posted by Michael Wonder on 30 Jun 2021
FDA grants fast track designation to CNS Pharmaceuticals for berubicin for the treatment of recurrent glioblastoma multiforme
29 June 2021 - FDA fast track designation for berubicin highlights the serious unmet medical need for new treatments for glioblastoma multiforme.
CNS Pharmaceuticals today announced that the U.S. FDA granted Fast Track Designation for its lead investigational drug, berubicin, for the treatment of patients with recurrent glioblastoma multiforme.
